EPA suggests safer flame retardants - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

EPA suggests safer flame retardants

Updated: Sep 26, 2013 02:22 PM

THURSDAY, Sept. 26 (HealthDay News) -- Safer alternatives to a toxic flame retardant chemical are presented in a new report from the U.S. Environmental Protection Agency.

The findings can help manufacturers select substitutes for hexabromocyclododecane (HBCD) in polystyrene building insulation, according to agency officials.

"While EPA continues to support much needed reform of the Toxics Substances Control Act, EPA is taking steps now to address the public's concern with certain flame-retardant chemicals, including making information available to companies to help them make decisions on safer chemicals," Jim Jones, EPA's assistant administrator for the Office of Chemical Safety and Pollution Prevention, said in an agency news release.

"The conclusions in this report are enabling companies who choose to move away from HBCD to do so with confidence that the potential for unintended consequences is minimized," he added.

The draft report -- Design for the Environment Alternatives Assessment -- identifies two alternatives to HBCD for use in polystyrene insulation. One of the alternatives, a butadiene styrene brominated copolymer, is anticipated to be safer than HBCD and is currently in commercial production in the United States.

As part of a broader effort involving flame-retardant chemicals, the EPA in March identified 20 such chemicals for full risk assessment. This includes developing full risk assessments on four of these chemicals, among them HBCD.

The information from the full risk assessments on these four chemicals will be used to better understand chemicals with similar structures and characteristics. The EPA said that if it identifies potential risks, it will take appropriate risk reduction measures.

Development of these risk assessments will begin later this year, and draft risk assessments will be available for expert review and public comment in 2014.

More information

Here's where you can find the EPA's draft report on hexabromocyclododecane.

Copyright © 2013 HealthDay. All rights reserved.

  • Health WatchMore>>

  • House approves VA health care overhaul

    House approves VA health care overhaul

    Wednesday, July 30 2014 9:12 PM EDT2014-07-31 01:12:40 GMT
    With a new Veterans Affairs secretary in place and an August recess looming, Congress is moving quickly to approve a compromise bill to refurbish the VA and improve veterans' health care.
    The House overwhelmingly approved a landmark bill Wednesday to help veterans avoid long waits for health care that have plagued the Veterans Affairs Department for years.
  • $1,000 Sovaldi now hepatitis treatment of choice

    $1,000 Sovaldi now hepatitis treatment of choice

    Wednesday, July 30 2014 8:58 PM EDT2014-07-31 00:58:45 GMT
    A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
    The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
  • Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.
    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.
*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.